Explore stories from Atlantic Canada.
Tentative trial dates set for four teens charged with murder | SaltWire #newsupdate #halifax #court - Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday.
As part of the deal, Totality Medispa will make a monetary payment to Lilly and will no longer use Lilly branding in the promotion of any of its products.The medi spa is expected to take several corrective actions including obtaining and distributing compounded tirzepatide products that are produced in compliance with U.S. federal law.
Lilly said in March it had found bacteria and high levels of impurities in products claiming to be compounded versions of tirzepatide and has sued several medical spas, weight-loss clinics and compounding pharmacies to stop them from selling products purporting to contain tirzepatide, the active ingredient in its weight loss and diabetes drugs.
Compounded drugs are custom-made medicines based on the same ingredients as branded versions, and often cheaper, but also subject to less regulatory scrutiny."While this agreement is an important step forward, this is not a problem that Lilly can solve alone.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Read more »
Lilly Raises 2024 Guidance as Zepbound Keeps Flying Off ShelvesEli Lilly & Co. raised its annual outlook for sales and profit as the company labored to satisfy soaring demand for its blockbuster weight-loss and diabetes drugs.
Read more »
Almost Every Dose of Lilly’s Zepbound Is in Shortage, FDA SaysNearly all doses of Eli Lilly & Co.’s weight-loss drug Zepbound will now be in shortage through at least the middle of the year as demand for the blockbuster injections continues to surge.
Read more »
Eli Lilly's weight loss drug could help sleep apnea patientsShares of Eli Lilly (LLY) are slightly above their flatline Wednesday morning after the pharmaceutical giant announced positive results from a clinical trial...
Read more »
Eli Lilly's GLP-1 demand drives up stock price post-Q1 resultsShares of Eli Lilly (LLY) are soaring in Tuesday's trading session after the company raised its full-year guidance, driven by the surging demand for its...
Read more »
Eli Lilly stock jumps on weight-loss drug sales forecastShares of Eli Lilly (LLY) are moving higher on Tuesday morning as the company reported its first-quarter earnings results, revealing a 26% year-over-year...
Read more »